Nevertheless, employing EPO in severe COVID-19 for improving acute and downstream outcome (long COVID), requires watchful and comprehensive safety management as much as in all other EPO indications and, in particular, when using high doses of EPO to obtain sufficient levels also in brain (Bartels et al. 2008). Here, EPO is linked to COVID-19.